Cedric Bisson
Partner at Teralys Capital
Montreal, Quebec
Overview
Work Experience
Partner
2011 - Current
Cedric Bisson is partner at Teralys Capital, where he focuses on healthcare and life sciences investments, as well as growth opportunities. Teralys Capital is Canada’s largest innovation-focused investor, financing private funds in IT, life sciences, and clean or industrial innovations, from early stage start-ups to expansion, growth and technology buy-outs.
Board member
2006
Mimetogen Pharmaceuticals is a Phase III clinical stage biotechnology company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases with high unmet medical needs. Mimetogen's lead compound, tavilermide, is a neurotrophin mimetic, in Phase III clinical trials for dry eye in the USA. In addition, the Company has developed novel therapeutic approaches for other ophthalmology indications including glaucoma and other degenerative diseases of the retina such as retinitis pigmentosa.
Chairman
2009
Procure is Quebec's largest charity fighting prostate cancer by means of education and awareness programs for men and their families, as well as the financing of research leveraging a proprietary world-class Biobank of biological materials and data to accelerate the discovery and development of new cures against prostate cancer.
Board Member and Investment Committee Member
2013
Grand Challenges Canada is dedicated to supporting Bold Ideas with Big Impact®. Funded by the Government of Canada and other partners, Grand Challenges Canada funds innovators in low- and middle-income countries and Canada. The bold ideas Grand Challenges Canada supports integrate science and technology, social and business innovation – known as Integrated Innovation®. One of the largest impact-first investors in Canada, Grand Challenges Canada has supported a pipeline of over 1,000 innovations in 95 countries. Grand Challenges Canada estimates that these innovations have the potential to save up to 1.6 million lives and improve up to 51 million lives by 2030.
Board Member and Investment Committee Member
2016 - 2020
Accel-Rx is Canada's national health sciences accelerator.
Chairman
2013 - 2018
The Montreal Biennale (La Biennale de Montréal or BNL MLT) is an international event focusing on visual arts and media arts. To attain its objectives, it breaks down the barriers between artistic disciplines, bringing together artists from the visual and media arts, architecture, design and film.
Board observer
2009 - 2013
BaroSense, a medical device company headquartered in Menlo Park, CA, focuses on the research and development of innovative, minimally invasive medical devices for the treatment of obesity.
Board member
2006 - 2011
Milestone Pharmaceuticals Inc. is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone’s lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.
Managing partner
2003 - 2011
Cedric Bisson was previously managing partner for life sciences at iNovia Capital (www.inovia.vc) in Montreal, Calgary and the USA, a private venture capital firm aimed at entrepreneurship and company building, during which he also created MSBi Valorisation (now Allgo, www.aligo.ca/en/), a seed technology transfer and investor firm focused principally on McGill University. Within life sciences, iNovia seeked out investment opportunities that provide clinically meaningful therapeutic benefits. The focus was on biopharmaceuticals and medical devices. While portfolio companies have global ambitions and proven management teams, they also strive to operate on a cash-efficient basis and to leverage shared expertise whenever possible.
Founder & Investment committee member
2003 - 2011
MSBi Valorisation brings to market promising technologies developed at McGill University, University of Sherbrooke and Bishop’s University, and their affiliated research centers. MSBiV is dedicated to supporting the creation of spin-offs as well licenses to existing companies.